Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-55.84M | $-19.65 |
| 2024 | $0.00 | $-55.65M | $-23.88 |
| 2023 | $0.00 | $-62.72M | $-27.04 |
| 2022 | $0.00 | $-74.73M | $-32.32 |
| 2021 | $0.00 | $-69.39M | $-30.15 |
Social Signal Score
Earnings
Wed, Nov 4(in 3 months)
Consensus estimate $-1.48 per share
Typical surprise -3.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-2.80 vs $-1.95miss
- Thu, May 7$-1.87 vs $-1.81miss
- Thu, Mar 5$-0.81 vs $-2.26beat
- Wed, Nov 5$-3.22 vs $-4.06beat
- Thu, Aug 7$-11.29 vs $-4.62miss
- Thu, May 1$-4.68 vs $-4.80beat
Estimates and results for NXTC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
NXTChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsprnewswire.com·5d ago·Neutral
Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001 Additional financing from a world-class investor syndicate further strengthens the combined company's balance sheet to accelerate development of AVR-001 Private placement and the previously announced concurrent private placement are expected to fully fund Avere's operating plan into 2029 SAN FRANCISCO, Aug. 10, 2026 /PRNewswire/ -- Avere Therapeutics, Inc. ("Avere" or the
View source ↗